dabur

Est.1979

Providing Integrated Research Solutions in Preclinical Biology

Modules

In Vitro Pharmacology

Metabolic Disease

Model In Vitro Model for evaluation of anti-diabetic activity
Test system
  • Type I: Insulinoma cell line (RIN5F/INS-1)
  • Type II: 3T3L-1 preadipocytes/adipocytes
End points
  • Quantitative glucose uptake in adipocytes
  • Cell based assays for inhibition of LPS induced IL-6 release in preadipocytes for insulin resistance
  • Adipolysis assay: Glycerol release in adipocytes
  • Adipogenesis assay: TG accumulation by Oil Red O staining in adipocytes
  • Insulin release assay: insulin secretion in insulinoma cell line
Model In vitro model for free fatty-acid- (FFA-) induced hepatic steatosis & insulin resistance
Test system
  • FFA challenged HepG2 cell line
Modals
  • Identification of non-cytotoxic doses of test item by MTT assay
  • Steatotic challenge with FFA and treatment with test item
End points
  • Lipid accumulation by Oil Red O staining
  • Quantitative ROS generation by fluorescence.
  • Estimation of pro-inflammatory cytokines by ELISA
  • Quantitative assessment of apoptosis
Model In vitro model for hepatic fibrosis and cirrhosis
Test system
  • Rat hepatic stellate cell line (HSC-T6)
Modals
  • Identification of non-cytotoxic doses of test item by MTT assay
  • Treatment with test item for specific time point
End points
  • Quantitative estimation of profibrotic markers (collagen and hyaluronic acid)
  • Cell proliferation by MTT assay
  • Quantitation of TGF-ß1 levels by ELISA
  • Quantitative assessment of apoptosis
ModelEvaluation of anti-osteoporotic potential of test molecule in vitro
Test system
  • Human osteosarcoma cell line (MG63)
Methods
  • Treatment of cells with test compounds
  • Determination of osteoblast differentiation through enhanced expression of :
    • Collagen synthesis
    • Alkaline Phosphatase
    • Osteocalcin
    • Osteopontin
    • Bone morphogenetic protein 2
  • Determination of potential to reduce the levels of ROS induced by H2O2
End pointsOsteogenic / anti-osteoporotic effects of test molecule.
ModelEvaluation of anti-osteoporotic potential of test molecule in vitro
Test system
  • Human osteosarcoma cell line (MG63)
Methods
    Treatment of cells with test compounds
  • Determination of osteoblast differentiation through enhanced expression of
  • Collagen synthesis
  • Alkaline Phosphatase
  • Osteocalcin
  • Osteopontin
  • Bone morphogenetic protein 2
  • Determination of potential to reduce the levels of ROS induced by H2O2
End pointsOsteogenic / anti-osteoporotic effects of test molecule.



ModelEnzyme assays
Test system
  • Purified Angiotensin-converting enzyme (ACE)
  • Purified soluble epoxide hydrolase (sEH) Purified Angiotensin-converting enzyme (ACE)
  • Purified soluble epoxide hydrolase (sEH)
Methods
  • ACE enzyme activity assay with TI and positive control by colorimetric metsEH enzyme activity assay with TI and positive control by fluorescence based method
End points
  • Inhibition of ACE enzyme activity by test item
  • Inhibition of sEH enzyme activity by test item
ModelIn vitro model for free fatty-acid- (FFA-) induced hepatic steatosis & insulin resistance
Test system
  • FFA challenged HepG2 cell line
Methods
  • Identification of non-cytotoxic doses of test item by MTT assay
  • Steatotic challenge with FFA and treatment with test item
End points
  • Lipid accumulation by Oil Red O staining
  • Quantitative ROS generation by fluorescence.
  • Estimation of pro-inflammatory cytokines by ELISA
  • Quantitative assessment of apoptosis
ModelIn vitro model for hepatic fibrosis and cirrhosis
Test system
  • Rat hepatic stellate cell line (HSC-T6
Methods
  • Identification of non-cytotoxic doses of test item by MTT assay
  • Treatment with test item for specific time point
End points
  • Quantitative estimation of profibrotic markers (collagen and hyaluronic acid)
  • Cell proliferation by MTT assay
  • Quantitation of TGF-ß1 levels by ELISA
  • Quantitative assessment of apoptosis
  • Get A Quote

    Get A Quote